Brain+

0,094

DKK

−0,42 %

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

4 investerare följer bolaget.

−0,42%

−5,06%

+13,29%

−24,96%

−48,5%

−48,5%

−95,57%

-

−96,59%

Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.

Börsvärde

19,94 mn DKK

Omsatt (värde)

39,31 tn DKK

Omsättning

-

EBIT%

-

P/E

-

Direktavkastnings- %

-

VisarAlla typer av innehåll

Pressmeddelande2024-12-10 07:45

Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

Pressmeddelande2024-12-05 07:51

Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

Pressmeddelande2024-11-21 14:30

Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto

Ger dig möjlighet att följa bolag och beställa notifikationer

Tillgång till analytikerkommentarer och rekommendationer

Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg

Skapa användarkonto

Pressmeddelande2024-11-01 10:57

Brain+ A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant

Pressmeddelande2024-10-21 09:54

Brain+ A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

Pressmeddelande2024-10-11 07:04

Brain+ A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions

Regulatoriskt pressmeddelande2024-10-07 09:50

Brain+ A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Pressmeddelande2024-10-02 08:32

Brain+ A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market

Regulatoriskt pressmeddelande2024-10-01 10:11

Brain+ A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions

Pressmeddelande2024-10-01 07:23

Brain+ A/S: Ayla - your CST Assistant has been registered in the UK as a certified Medical Device Software for dementia therapy

Pressmeddelande2024-09-25 08:43

Brain+ A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK

Pressmeddelande2024-09-23 10:15

Brain+ A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization

Regulatoriskt pressmeddelande2024-09-20 06:43

Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%

Regulatoriskt pressmeddelande2024-09-17 08:46

Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4

Pressmeddelande2024-09-13 08:33

Brain+ A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027

Regulatoriskt pressmeddelande2024-09-13 07:08

Brain+ A/S announces the exercise price for its warrants of series TO 4

Pressmeddelande2024-09-05 07:30

Brain+ A/S: First patient enrolled in a clinical trial to evaluate Brain+' next generation cognitive training technology for Mild Cognitive Impairment

Pressmeddelande2024-09-03 06:30

Brain+ A/S: Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit

Pressmeddelande2024-08-30 10:35

Brain+ A/S: Invitation to Investor Webinar on Tues 3 Sept 2024 at 16:00 CEST: H1 2024 report and new Chief Commercial Officer

Regulatoriskt pressmeddelande2024-08-29 17:08

Brain+ A/S: H1 2024: Brain+ has executed successfully in accordance with its UK-focused commercial strategy towards proof-of-business and realized financial results as expected

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.